{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T18:34:08Z","timestamp":1790447648201,"version":"4.1.0"},"reference-count":81,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004914","name":"Ferring Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004914","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.euo.2020.02.006","type":"journal-article","created":{"date-parts":[[2020,3,20]],"date-time":"2020-03-20T01:47:16Z","timestamp":1584668836000},"page":"318-340","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["Evidence-based Assessment of Current and Emerging Bladder-sparing Therapies for Non\u2013muscle-invasive Bladder Cancer After Bacillus Calmette-Guerin Therapy: A Systematic Review and Meta-analysis"],"prefix":"10.1016","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3546-9928","authenticated-orcid":false,"given":"Ashish M.","family":"Kamat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth P.","family":"Lerner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7202-6427","authenticated-orcid":false,"given":"Michael","family":"O\u2019Donnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihaela V.","family":"Georgieva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brant A.","family":"Inman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wassim","family":"Kassouf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen A.","family":"Boorjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark D.","family":"Tyson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Girish S.","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam S.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Badrinath R.","family":"Konety","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert S.","family":"Svatek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjun","family":"Balar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Alfred","family":"Witjes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2020.02.006_bib0005","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.eururo.2012.07.033","article-title":"Epidemiology and risk factors of urothelial bladder cancer","volume":"63","author":"Burger","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2020.02.006_bib0010","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline","volume":"196","author":"Chang","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2020.02.006_bib0015","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.eururo.2016.05.041","article-title":"EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016","volume":"71","author":"Babjuk","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2020.02.006_bib0020","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1016\/S0140-6736(16)30512-8","article-title":"Bladder cancer","volume":"388","author":"Kamat","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.euo.2020.02.006_bib0025","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study","volume":"163","author":"Lamm","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2020.02.006_bib0030","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/cncr.30392","article-title":"Non-muscle-invasive bladder cancer: Intravesical treatments beyond bacille Calmette-Guerin","volume":"123","author":"Packiam","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.euo.2020.02.006_bib0035","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.eururo.2006.01.017","article-title":"Management of BCG failures in superficial bladder cancer: a review","volume":"49","author":"Witjes","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2020.02.006_bib0040","doi-asserted-by":"crossref","first-page":"5680","DOI":"10.1200\/JCO.2009.23.6901","article-title":"Bladder cancer: narrowing the gap between evidence and practice","volume":"27","author":"Hussain","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2020.02.006_bib0045","unstructured":"US Food and Drug Administration. 2018. https:\/\/www.fda.gov\/media\/101468\/download."},{"key":"10.1016\/j.euo.2020.02.006_bib0050","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.urolonc.2017.12.020","article-title":"Role of immunotherapy in bacillus Calmette-Guerin-unresponsive non-muscle invasive bladder cancer","volume":"36","author":"Mukherjee","year":"2018","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2020.02.006_bib0055","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.eururo.2018.04.012","article-title":"Treatment options for patients with recurrent tumors after BCG therapy: are we ignoring the obvious?","volume":"74","author":"Li","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2020.02.006_bib0060","series-title":"NCCN guidelines insights: bladder cancer","author":"Flaig","year":"2019"},{"key":"10.1016\/j.euo.2020.02.006_bib0065","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.eururo.2014.12.002","article-title":"Trends in operative caseload and mortality rates after radical cystectomy for bladder cancer in England for 1998\u20132010","volume":"67","author":"Hounsome","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2020.02.006_bib0070","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.juro.2010.06.007","article-title":"Early and late perioperative outcomes following radical cystectomy: 90-day readmissions, morbidity and mortality in a contemporary series","volume":"184","author":"Stimson","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2020.02.006_bib0075","article-title":"How should I manage a patient with tumor recurrence despite adequate bacille Calmette-Guerin?","author":"Kamat","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2020.02.006_bib0080","unstructured":"Babjuk M., Burger M., Comperat E.M., et al. Statement concerning the shortage of BCG vaccine from the EAU Guidelines Panel on Non-muscle-invasive Bladder Cancer. https:\/\/uroweb.org\/wp-content\/uploads\/Updated-statement-concerning-the-shortage-of-BCG-vaccine-NMIBC-Panel-2018.pdf."},{"key":"10.1016\/j.euo.2020.02.006_bib0085","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.euo.2020.02.006_bib0090","series-title":"Cochrane handbook for systematic reviews of interventions","author":"Higgins","year":"2019"},{"key":"10.1016\/j.euo.2020.02.006_bib0095","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/2049-3258-72-39","article-title":"Metaprop: a Stata command to perform meta-analysis of binomial data","volume":"72","author":"Nyaga","year":"2014","journal-title":"Arch Public Health"},{"key":"10.1016\/j.euo.2020.02.006_bib0100","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.euo.2020.02.006_bib0105","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.euo.2020.02.006_bib0110","doi-asserted-by":"crossref","first-page":"e1050","DOI":"10.1016\/S1569-9056(18)31563-X","article-title":"Results of the phase-I open-label clinical trial SAKK 06\/14 assessing safety of intravesical instillation of the recombinant BCG VPM1002BC in patients with non-muscle invasive bladder cancer and previous failure to conventional BCG therapy","volume":"17","author":"Rentsch","year":"2018","journal-title":"Eur Urol Suppl"},{"key":"10.1016\/j.euo.2020.02.006_bib0115","first-page":"e620","article-title":"MP43-09 Phase I trial of intravesical bacillus Calmette-Gu\u00e9rin combined with intravenous pembrolizumab in high grade nonmuscle invasive bladder cancer","volume":"201","author":"Alanee","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2020.02.006_bib0120","doi-asserted-by":"crossref","first-page":"e336","DOI":"10.1016\/j.juro.2016.03.084","article-title":"A phase 1\/2 study of albumin-bound rapamycin nanoparticles in bacillus Calmette-Guerin refractory non-muscle invasive bladder cancer","volume":"195","author":"McKiernan","year":"2016","journal-title":"J Urol"},{"issue":"4 Suppl","key":"10.1016\/j.euo.2020.02.006_bib0125","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/S0022-5347(09)61929-7","article-title":"Preliminary results of a phase I study with intravesical administration of adenoviral-mediated interferon-\u03b1 for patients with BCG refractory transitional cell carcinoma of the bladder","volume":"181","author":"Fisher","year":"2009","journal-title":"J Urol"},{"issue":"6_suppl","key":"10.1016\/j.euo.2020.02.006_bib0130","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1200\/JCO.2017.35.6_suppl.313","article-title":"A phase I trial for the use of intravesical cabazitaxel, gemcitabine, and cisplatin (CGC) in the treatment of BCG-refractory nonmuscle invasive urothelial carcinoma of the bladder","volume":"35","author":"DeCastro","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2020.02.006_bib0135","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.juro.2010.09.073","article-title":"Paclitaxel-hyaluronic acid for intravesical therapy of bacillus Calmette-Guerin refractory carcinoma in situ of the bladder: results of a phase I study","volume":"185","author":"Bassi","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2020.02.006_bib0140","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1016\/j.juro.2012.07.097","article-title":"A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer","volume":"188","author":"Burke","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2020.02.006_bib0145","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1002\/cncr.24914","article-title":"Gemcitabine versus bacille Calmette-Guerin after initial bacille Calmette-Guerin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial","volume":"116","author":"Di Lorenzo","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.euo.2020.02.006_bib0150","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.juro.2013.03.030","article-title":"Phase I trial of intravesical recombinant adenovirus mediated interferon-alpha2b formulated in Syn3 for Bacillus Calmette-Guerin failures in nonmuscle invasive bladder cancer","volume":"190","author":"Dinney","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2020.02.006_bib0155","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1016\/j.urolonc.2012.04.010","article-title":"Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Guerin","volume":"31","author":"Dinney","year":"2013","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2020.02.006_bib0160","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1038\/sj.bjc.6604074","article-title":"Activity of endovesical gemcitabine in BCG-refractory bladder cancer patients: a translational study","volume":"97","author":"Gunelli","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1016\/j.euo.2020.02.006_bib0165","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.urolonc.2008.05.004","article-title":"Phase II study of intravesical therapy with AD32 in patients with papillary urothelial carcinoma or carcinoma in situ (CIS) refractory to prior therapy with bacillus Calmette-Guerin (E3897): a trial of the Eastern Cooperative Oncology Group","volume":"27","author":"Ignatoff","year":"2009","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2020.02.006_bib0170","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3109\/02656736.2014.882021","article-title":"A pilot clinical trial of intravesical mitomycin-C and external deep pelvic hyperthermia for non-muscle-invasive bladder cancer","volume":"30","author":"Inman","year":"2014","journal-title":"Int J Hyperthermia"},{"key":"10.1016\/j.euo.2020.02.006_bib0175","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.urolonc.2005.11.026","article-title":"Final results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer","volume":"24","author":"Joudi","year":"2006","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2020.02.006_bib0180","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3233\/BLC-160084","article-title":"Efficacy of Mycobacterium phlei cell wall-nucleic acid complex (MCNA) in BCG-unresponsive patients","volume":"3","author":"Li","year":"2017","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.euo.2020.02.006_bib0185","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.juro.2014.09.109","article-title":"Efficacy and safety of MCNA in patients with nonmuscle invasive bladder cancer at high risk for recurrence and progression after failed treatment with bacillus Calmette-Guerin","volume":"193","author":"Morales","year":"2014","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2020.02.006_bib0190","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.urolonc.2017.07.005","article-title":"An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: interim results","volume":"36","author":"Packiam","year":"2017","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2020.02.006_bib0195","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/CAD.0b013e3283324d83","article-title":"Is gemcitabine an option in BCG-refractory nonmuscle-invasive bladder cancer? A single-arm prospective trial","volume":"21","author":"Perdona","year":"2010","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.euo.2020.02.006_bib0200","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1186\/s12885-018-5134-7","article-title":"ElectroMotive drug administration (EMDA) of Mitomycin C as first-line salvage therapy in high risk \u201cBCG failure\u201d non muscle invasive bladder cancer: 3 years follow-up outcomes","volume":"18","author":"Racioppi","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.euo.2020.02.006_bib0205","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.juro.2011.04.073","article-title":"Factors affecting response to bacillus Calmette-Guerin plus interferon for urothelial carcinoma in situ","volume":"186","author":"Rosevear","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2020.02.006_bib0210","doi-asserted-by":"crossref","first-page":"3410","DOI":"10.1200\/JCO.2017.72.3064","article-title":"Intravesical rAd-IFNalpha\/Syn3 for patients with high-grade, bacillus Calmette-Guerin-refractory or relapsed non-muscle-invasive bladder cancer: a phase II randomized study","volume":"35","author":"Shore","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2020.02.006_bib0215","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.juro.2013.04.031","article-title":"SWOG S0353: Phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical bacillus Calmette-Guerin","volume":"190","author":"Skinner","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2020.02.006_bib0220","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.eururo.2018.09.005","volume":"75","author":"Tan","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2020.02.006_bib0225","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.urology.2017.01.018","article-title":"Long-term survival outcomes with intravesical nanoparticle albumin-bound paclitaxel for recurrent non-muscle-invasive bladder cancer after previous bacillus Calmette-Guerin therapy","volume":"103","author":"Robins","year":"2017","journal-title":"Urology"},{"issue":"15_suppl","key":"10.1016\/j.euo.2020.02.006_bib0230","doi-asserted-by":"crossref","first-page":"4561","DOI":"10.1200\/JCO.2019.37.15_suppl.4561","article-title":"Preliminary phase 2 clinical results of IL-15R\u03b1Fc superagonist N-803 with BCG in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) patients","volume":"37","author":"Chamie","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2020.02.006_bib0235","series-title":"A phase I trial of intravesical cabazitaxel, gemcitabine, and cisplatin (CGC) for the treatment of non-muscle invasive BCG unresponsive urothelial carcinoma of the bladder","author":"DeCastro","year":"2019"},{"key":"10.1016\/j.euo.2020.02.006_bib0240","doi-asserted-by":"crossref","first-page":"e1167","DOI":"10.1016\/j.juro.2018.03.099","article-title":"LBA27 Phase 3 study of Vicinium in BCG-unresponsive non-muscle invasive bladder cancer: initial results","volume":"199","author":"Dickstein","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2020.02.006_bib0245","doi-asserted-by":"crossref","first-page":"e570","DOI":"10.1016\/j.juro.2014.02.1586","article-title":"MP56-18 Are intermediate risk NMIBC failing BCG a high risk disease? LONG term results of a phase II study on second line intravesical gemcitabine","volume":"191","author":"Fiorito","year":"2014","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2020.02.006_bib0250","first-page":"e312","article-title":"PD18-04 A phase 1 safety study of ONCOFID-P-B administered for 12 consecutive weeks in BCG unresponsive\/intolerant patients with bladder carcinoma in situ (CIS): preliminary results","volume":"201","author":"Hurle","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2020.02.006_bib0255","doi-asserted-by":"crossref","first-page":"S138","DOI":"10.1016\/j.jamcollsurg.2016.06.293","article-title":"Chemotherapeutic role of intravesical gemcitabine and mitomycin C for high-risk nonmuscle invasive bladder carcinoma: a randomized trial","volume":"223","author":"Jayant","year":"2016","journal-title":"J Am Coll Surg"},{"key":"10.1016\/j.euo.2020.02.006_bib0260","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/j.urology.2009.07.1142","article-title":"POD07.03: Treatment with intravesical Vicinium\u2122 results in durable responses in patients with carcinoma in situ (CIS) previously treated with bacille Calmette-Gu\u00e9rin (BCG)","volume":"74","author":"Kowalski","year":"2009","journal-title":"Urology"},{"key":"10.1016\/j.euo.2020.02.006_bib0265","doi-asserted-by":"crossref","first-page":"e142","DOI":"10.1016\/j.juro.2016.02.2500","article-title":"MP13-19 A phase II\/III trial of CG0070, an oncolytic adenovirus, for BCG-refractory non-muscle-invasive bladder cancer (NMIBC)","volume":"195","author":"Packiam","year":"2016","journal-title":"J Urol"},{"issue":"Suppl 4","key":"10.1016\/j.euo.2020.02.006_bib0270","first-page":"e617","article-title":"MP43-02 CG0070, an oncolytic adenovirus, for BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC): 18 month follow-up from a multicenter phase II trial","volume":"201","author":"Packiam","year":"2019","journal-title":"J Urol"},{"issue":"Suppl 3","key":"10.1016\/j.euo.2020.02.006_bib0275","first-page":"1","article-title":"Intravesical IFN-a and BCG immunotherapy for patients with recurrent bladder cancer after previous BCG therapy","volume":"113","author":"Rahmat","year":"2014","journal-title":"BJU Int"},{"issue":"15_suppl","key":"10.1016\/j.euo.2020.02.006_bib0280","doi-asserted-by":"crossref","first-page":"4530","DOI":"10.1200\/JCO.2019.37.15_suppl.4530","article-title":"Pembrolizumab (pembro) for patients (pts) with high-risk (HR) non\u2013muscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Gu\u00e9rin (BCG): updated follow-up from KEYNOTE-057","volume":"37","author":"Wit","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2020.02.006_bib0285","series-title":"VISTA, phase 3 trial of Vicinium, an EpCAM-targeted Pseudomonas exotoxin, in BCG-unresponsive non-muscle invasive bladder cancer","author":"Dickstein","year":"2018"},{"key":"10.1016\/j.euo.2020.02.006_bib0290","doi-asserted-by":"crossref","first-page":"e915","DOI":"10.1016\/j.juro.2017.03.039","article-title":"PNFLBA-13 Interim results from a single-arm multicenter phase II trial of CG0070, an oncolytic adenovirus, for BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC)","volume":"197","author":"Packiam","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2020.02.006_bib0295","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.urolonc.2008.11.019","article-title":"Sequential intravesical gemcitabine and mitomycin C chemotherapy regimen in patients with non-muscle invasive bladder cancer","volume":"28","author":"Breyer","year":"2010","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2020.02.006_bib0300","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.juro.2009.06.017","article-title":"Combined thermo-chemotherapy for recurrent bladder cancer after bacillus Calmette-Guerin","volume":"182","author":"Nativ","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2020.02.006_bib0305","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.urolonc.2012.02.007","article-title":"Photodynamic therapy of bladder cancer - a phase I study using hexaminolevulinate (HAL)","volume":"31","author":"Bader","year":"2013","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2020.02.006_bib0310","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/bju.13088","article-title":"Intravesical gemcitabine in combination with mitomycin C as salvage treatment in recurrent non-muscle-invasive bladder cancer","volume":"117","author":"Cockerill","year":"2016","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2020.02.006_bib0315","doi-asserted-by":"crossref","first-page":"395","DOI":"10.3233\/BLC-180191","article-title":"Hyperthermic intravesical chemotherapy for BCG unresponsive non-muscle invasive bladder cancer patients","volume":"4","author":"de Jong","year":"2018","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.euo.2020.02.006_bib0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2017.07.024","article-title":"Quadruple immunotherapy of bacillus Calmette-Guerin, interferon, interleukin-2, and granulocyte-macrophage colony-stimulating factor as salvage therapy for non-muscle-invasive bladder cancer","volume":"35","author":"Steinberg","year":"2017","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2020.02.006_bib0325","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3233\/BLC-150008","article-title":"Sequential intravesical gemcitabine and docetaxel for the salvage treatment of non-muscle invasive bladder cancer","volume":"1","author":"Steinberg","year":"2015","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.euo.2020.02.006_bib0330","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.juro.2012.10.068","article-title":"Long-term survival outcomes with intravesical docetaxel for recurrent nonmuscle invasive bladder cancer after previous bacillus Calmette-Guerin therapy","volume":"189","author":"Barlow","year":"2013","journal-title":"J Urol"},{"issue":"3 Part 1","key":"10.1016\/j.euo.2020.02.006_bib0335","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S0022-5347(17)40882-2","article-title":"Intravesical combination chemotherapy with mitomycin C and doxorubicin for carcinoma in situ of the bladder","volume":"141","author":"Fukui","year":"1989","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2020.02.006_bib0340","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.juro.2013.04.077","article-title":"Efficacy and safety of photodynamic therapy for recurrent, high grade nonmuscle invasive bladder cancer refractory or intolerant to bacille Calmette-Guerin immunotherapy","volume":"190","author":"Lee","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2020.02.006_bib0345","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3233\/BLC-170126","article-title":"Oncological outcomes of sequential intravesical gemcitabine and docetaxel in patients with non-muscle invasive bladder cancer","volume":"3","author":"Milbar","year":"2017","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.euo.2020.02.006_bib0350","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2013.01.009","article-title":"Multi-institutional analysis of sequential intravesical gemcitabine and mitomycin C chemotherapy for non-muscle invasive bladder cancer","volume":"32","author":"Lightfoot","year":"2014","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2020.02.006_bib0355","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0022-5347(18)33076-3","article-title":"840: Intravesical sequential gemcitabine-mitomycin chemotherapy as salvage treatment for patients with refractory superficial bladder cancer","volume":"175","author":"Maymi","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2020.02.006_bib0360","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S0090-4295(02)02164-7","article-title":"Whole bladder photodynamic therapy with 5-aminolevulinic acid using a white light source","volume":"61","author":"Waidelich","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.euo.2020.02.006_bib0365","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/nrurol.2017.16","article-title":"BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG","volume":"14","author":"Kamat","year":"2017","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.euo.2020.02.006_bib0370","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1200\/JCO.2015.64.4070","article-title":"Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: recommendations from the International Bladder Cancer Group","volume":"34","author":"Kamat","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2020.02.006_bib0375","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2014.02.020","article-title":"BCG-refractory vs. BCG-relapsing non-muscle-invasive bladder cancer: a prospective cohort outcomes study","volume":"33","author":"Herr","year":"2015","journal-title":"Urol Oncol"},{"issue":"6 Pt B","key":"10.1016\/j.euo.2020.02.006_bib0380","first-page":"E216","article-title":"Prognostic significance of bacillus Calmette-Guerin failure classification in non-muscle-invasive bladder cancer","volume":"110","author":"Shirakawa","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2020.02.006_bib0385","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.eururo.2009.12.024","volume":"57","author":"Sylvester","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2020.02.006_bib0390","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.euo.2018.08.013","article-title":"Using grade of recurrent tumor to guide further therapy while on bacillus Calmette-Guerin: low-grade recurrences are not benign","volume":"2","author":"Li","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2020.02.006_bib0395","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.eururo.2018.09.001","article-title":"Epidemiology of bladder cancer: a systematic review and contemporary update of risk factors in 2018","volume":"74","author":"Cumberbatch","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2020.02.006_bib0400","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.euo.2018.05.002","article-title":"Role of checkpoint inhibition in localized bladder cancer","volume":"1","author":"Hahn","year":"2018","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2020.02.006_bib0405","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0022-5347(05)67799-3","article-title":"Efficacy and safety of valrubicin for the treatment of bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group","volume":"163","author":"Steinberg","year":"2000","journal-title":"J Urol"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931120300316?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931120300316?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T15:46:07Z","timestamp":1762875967000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931120300316"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":81,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S2588931120300316"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2020.02.006","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evidence-based Assessment of Current and Emerging Bladder-sparing Therapies for Non\u2013muscle-invasive Bladder Cancer After Bacillus Calmette-Guerin Therapy: A Systematic Review and Meta-analysis","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2020.02.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}